五大主题论坛齐聚：第三届创新抗体药物发现论坛，第三届细胞与基因治疗创新论坛，第二届CDMO未来发展论坛，临床前与临床开发论坛，小分子与创新药论坛

会议规模：1200人+

时间：2022年1月11-12日

地点：上海

支持单位：上海市生物医药行业协会，广东药谷，深圳生物医药促进会

第三届创新抗体药物发现论坛主要话题：

ADCs全球与国内趋势纵览/Overview of ADCs Global and Domestic Trends

ADC药物定点偶联技术及成药性的研究趋势纵览/ Overview of the research

ADC药物研发面临的挑战和机遇/Challenges and opportunities facing ADC干细胞药物的发现研究

下一代ADC药物研发/Next-generation ADC drug development

抗体偶联药物（ADC）的临床方案设计与检测/ Design and testing of the clinical program of antibody-conjugated drugs (ADC)

ADC药物蓬勃发展: CDMO发展机遇和挑战/ ADC drugs are booming: CDMO development opportunities and challenges

迎接挑战与机遇，抗体药物研发战略布局/Facing challenges and opportunities, the strategic layout of antibody drug R&D

CD28是否会打破双特异抗体的格局/Will CD28 break the pattern of bispecific antibodies?

双特异性抗体创新药研发: 新靶点和组合/Bispecific antibody innovation drug development: new targets and combinations

新一代免疫检查点药物开发/Development of a new generation of immune checkpoint drugs

圆桌讨论: 百花齐放的双抗/The booming of Bispecific antibody drug development

重组蛋白类药物的研发现状与趋势/Current status and trend of research and development of recombinant protein drugs

靶向CD47/SIRPα药物研发进展和未来展望/Development and future prospects of drugs targeting CD47/SIRPα

以VEGF(R)为靶点药物的研发进展/Development progress of VEGF(R) target drugs

靶点ROR1会是下一个PD-1？/Will the target ROR1 be the next PD-1?

靶向NK细胞治疗肿瘤的双特异性抗体药物开发/Development of bispecific antibody drugs targeting NK cells to treat tumors

Claudin 18.2下一代创新免疫疗法黑马/Claudin 18.2 The next generation of innovative immunotherapy dark horse

第三届细胞与基因治疗创新论坛：

细胞免疫治疗产业发展趋势与政策环境解读/Development Trends and Policies of Cellular Immunotherapy Industry

CART产品开发新靶点新思路/CART product development new targets and new ideas

CART免疫细胞治疗的工艺开发，验证和产业化/Process development, verification and industrialization of CART immune cell therapy

双靶点CAR-T细胞治疗癌症的研究进展和展望/Research progress and prospects of dual-target CAR-T cell therapy for cancer

治疗肝癌CAR-T细胞产品的设计和临床研究/Design and clinical research of CAR-T cell products for the treatment of liver cancer

小组讨论: CAR-T细胞治疗火热的当下面临的潜在问题，未来破局之道 The potential problems faced by CAR-T cell therapy at the moment, and the future outlook

广谱多功能CAR-NK 细胞药物的研发/Development of Multifunctional Integrated CAR-NK Cell Drug

基因治疗药物研发与分析/Gene therapy drug development and analysis

溶瘤病毒产品的研发进展/Research and development progress of oncolytic virus products

下一代腺病毒载体+ 新技术助基因治疗腾飞/Next-generation Adenovirus Vector + New Technology Helps Gene Therapy Take Off

基因编辑技术及其应用/Gene editing technology and its application

从小众到大众→通用CAR-T未来已来/From niche to mass → General CAR-T's future is here

肿瘤微环境下的下一代细胞治疗产品开发/Development of next-generation cell therapy products in the tumor microenvironment

病毒载体开发和工艺优化/Viral vector development and process optimization

溶瘤病毒联合PD1/PD-L1治疗癌症/Oncolytic virus combined with PD1/PD-L1 to treat cancer

AAV在眼科疾病领域中的应用突破/Breakthrough in the application of AAV in the field of ophthalmic diseases

溶瘤病毒产品商业化生产的机遇和挑战/Opportunities and challenges for commercial production of oncolytic virus products

第二届CDMO未来发展论坛主要话题：

抗体药物生产上游工艺开发及优化/Upstream process development and optimization of antibody drug production

抗体药物生产下游连续工艺：当下趋势与挑战/Progression of continuous downstream processing of monoclonal antibodies: current trends and challenges

CDMO角度分析细胞与基因治疗产业化面临的挑战和未来展望/CDMO analysis of the challenges and future prospects of the industrialization of cell and gene therapy

抗体药物商业化生产的关键要素/The key elements of the commercial production of antibody drugs

基因治疗药物的生产工艺开发策略和案例分享/Gene therapy drug production process development strategy and case sharing

圆桌讨论：中国CDMO未来发展之路/Panel Discussion：The future development of China's CDMO

全球一次性工艺技术市场与展望/Global Single-use Bioprocessing Market Outlook and Forecast

一次性工艺技术在生物制药领域的应用机会与实践/Application opportunities and practices of disposable process technology in the field of biopharmaceuticals

生物制药：一次性生产工艺VS不锈钢生物反应器/Single-Use VS StainlessSteel Bioreactors for Biopharma

双抗CMC下游纯化及分析方法开发案例分享/Case sharing of double antibody CMC downstream purification and analysis method development

GmP生产中生产工艺变更和管理/Production process change and management in GmP production

药品全生命周期工艺开发和技术转移中的质量保证/Quality Assurance in Process Development and Technology Transfer of Drugs in Whole Life Cycle

全生命周期管理助力生物制药创新/Driving Innovation of BioPharma Products Through Life Cycle Planning

数字化技术助力生物药GMP生产/Pharma 4.0: Why digitize production

创新+国际化，打造全球领先的质量管理体系/Innovation + internationalization, to build a world-leading quality management system

基于QbD的细胞培养工艺开发

CDMO赋能中国生物制药发展/CDMO empowers China's biopharmaceutical development

临床前与临床开发论坛：

抗体偶联药物药代动力学研究进展/Research progress on the PK of antibody-conjugated drugs

生物药的免疫原性评价/Evaluation of immunogenicity of biological drugs

生物药的GLP安全性评价/GLP safety evaluation of biological drugs

临床前与临床试验数据的过程管理/Process management of pre-clinical and clinical trial data

小组讨论: 如何规范生物药的临床前研究，加快IND申报进程/Panel discussion: How to standardize the preclinical research of biological drugs and speed up the IND application process

创新药临床实验设计的考量/Considerations for the design of clinical trials of innovative drugs

人源化小鼠模型在肿瘤免疫新药研发中的应用/Application of humanized mouse model in the development of new tumor immune drugs

生物药国际多中心临床试验的成功要素/Successful factors for international multi-center clinical trials of biological drugs

ADC药物CMC工艺开发及临床研究策略/ADC drug CMC process development and clinical research strategy

生物制药IND到上市全生命周期CMC的重要性/The importance of CMC from biopharmaceutical IND to listing

创新生物药PK-PD研究中生物分析的考虑/Considerations of biological analysis in the research of innovative biological drugs PK-PD

数字化在临床使用中的应用/Application of digitization in clinical use

IND阶段CMC的评审要点/CMC review points in the IND phase

圆桌讨论: 中国临床前CRO行业发展现状及未来方向/Panel Discussion: Development Status and Future Direction of China's Preclinical CRO

免疫细胞治疗产品药学研究/CMC Research of Immune Cell Therapy Products

创新生物药临床研发中药学的挑战和应对/Challenges and countermeasures of CMC in clinical research and development of innovative biopharma

药物安全和药物警戒

小分子与创新药论坛：

小分子创新药物研发趋势和战略/Trends and Strategies of Small Molecule Innovative Drug Development

免疫代谢小分子药物的未来创新研发之路/The future innovative R&D road of immunometabolic small molecule drugs

小分子药物和肿瘤免疫联合治疗：未来突破方向/Combination therapy of small molecule drugs and tumor immunity: a breakthrough direction in the future

小分子药物开发热门靶点及全球研发现状/Popular targets for small molecule drug development and global R&D status

Kras靶向抗癌药物开发走向何方？/Where is Kras's targeted anti-cancer drug development going?

NASH新药研发：离成功还有多远/NASH new drug development: how far is it from success

AI赋能小分子多肽药物研发/AI empowers R&D of small molecule peptide drugs

一次性工艺技术在生物制药领域的应用机会与实践/Application opportunities and practices of disposable process technology in the field of biopharmaceuticals

新一代小分子药物晶体结构的解析技术——MicroED/A new generation of small molecule drug crystal structure analysis technology——MicroED

5 抗肿瘤新药SHP2抑制剂的开发/The discovery and development of First in Class SHP2 inhibitors

制剂创新和产品改良：布局、实践和展望/Formulation innovation and product improvement: layout, practice and outlook

创新药物制剂开发策略/Antibody drug formulation development strategy

靶向RNA小分子药物开发的进展和未来展望/Progress and future prospects of targeted RNA small molecule drug development

Protac技术助力新药研发/Protac technology helps new drug development

505 (b)(2)口服产品开发中常用的给药技术/505 (b)(2) Commonly used drug delivery techniques in the development of oral products

抗肿瘤多肽类药物研发进展和趋势/Progress and trends in the development of anti-tumor peptide drugs

多肽偶联药物(PDC) ——继ADC之后，新一代肿瘤靶向药物已然来临/Polypeptide-conjugated drugs (PDC)-after ADC, a new generation of tumor-targeted drugs has arrived

重组蛋白类药物的研发现状与趋势/Current status and trend of research and development of recombinant protein drugs

60个展位火热预订，演讲赞助，椅背赞助，横幅赞助等火热开选，9月1日前更有75折优惠等你抢！

往届会后报告，往届参会人员名单，展台，赞助方案等请联系大会组委会工作人员：

Mr. Arthur Yang–Sales & Marketing Director

杨先生—峰会营销总监 邮箱： yang@peakevents.org
手机/Mobile: +86 159 0054 6273（微信同号）